U.S. Catheters Market Size, Share & Forecast 2026–2032
Report Highlights
- ✓Country: United States
- ✓Market: Catheters Market
- ✓Market Size 2024: USD 6.8 billion
- ✓Market Size 2032: USD 9.9 billion
- ✓CAGR: 4.8%
- ✓Base Year: 2025
- ✓Forecast Period: 2026–2032
Analyst Recommendation — Pursue Antimicrobial GPO Contracts: Medical device manufacturers should secure 510(k) clearance for an antimicrobial catheter SKU and file a GPO contract with Vizient or Premier before Q4 2026. Hospital value analysis cycles run annually, so late entry forfeits a full budget year.
Catheters in the U.S.: Market Overview
The U.S. catheters market is among the most reimbursement-driven medical device categories in the world, valued at USD 6.8 billion in 2024. It differs from the global norm, where Asia Pacific manufacturing and low-cost disposable volume set price points. In the United States, buyers pay premium prices for antimicrobial, hydrophilic, and safety-engineered products because payment rules, not unit cost, determine what hospitals and home-care providers purchase. Demand is anchored in acute care, dialysis, and cardiovascular procedures rather than consumer or veterinary channels.
Market structure is concentrated at the top and fragmented below. Becton Dickinson, Medtronic, Teleflex, and Boston Scientific hold the majority of hospital urology, vascular access, and interventional revenue, while Cook Medical, Merit Medical, and Coloplast compete in specialty niches. Thousands of hospitals, ambulatory surgery centers, and dialysis facilities buy through group purchasing organizations such as Vizient and Premier, which consolidate volume into multi-year contracts. This purchasing concentration gives incumbents durable access to high-volume accounts and raises the cost of switching suppliers.
Growth Drivers in U.S. Catheter Demand
Demographic ageing is the most durable driver. Adults aged 65 and older represented about 18 percent of the U.S. population in 2024 according to the U.S. Census Bureau, and this cohort accounts for the majority of indwelling urinary catheter use in long-term care and home health. Medicare enrollment, which exceeds 68 million beneficiaries, expands demand for chronic urinary care and vascular access management. Each additional beneficiary in skilled nursing or home health settings generates recurring catheter replacement volume tied to fixed reimbursement schedules.
Chronic kidney disease is the second driver. More than 800,000 Americans live with end-stage renal disease according to the United States Renal Data System, and many depend on tunneled dialysis catheters as a bridge to permanent fistulas. CMS's ESRD Treatment Choices model and the bundled dialysis payment system reward home and in-center dialysis growth. Cardiovascular interventional volume is the third driver, as Medicare coverage of transcatheter aortic valve replacement and electrophysiology ablation sustains guiding catheter demand in hospital cath labs.
Market Restraints and Entry Barriers
FDA premarket clearance imposes the first barrier. Most catheters are Class II devices requiring 510(k) clearance under 21 CFR Part 807, while drug-coated or new-indication designs can trigger a Class III premarket approval pathway. Manufacturers must also comply with the Quality Management System Regulation, effective February 2, 2026, which aligns 21 CFR Part 820 with ISO 13485:2016. Clearance timelines and documentation costs favor established firms with existing design history files and regulatory staff.
Pricing and purchasing controls raise the second barrier. GPO contracts and hospital value analysis committees award annual or multi-year exclusive agreements, leaving newcomers little access to acute-care volume. Medicare's DMEPOS Competitive Bidding Program sets competitive payment amounts for urological supplies sold to home patients, compressing margins for intermittent and external catheters. Section 301 tariffs on China-origin medical goods raise input costs for silicone and PVC tubing, squeezing importers who lack domestic finishing capacity.
Market Opportunities in U.S. Catheters
Antimicrobial and CAUTI-reducing catheters offer the nearest entry point. CMS's Hospital-Acquired Condition Reduction Program penalizes hospitals with catheter-associated urinary tract infection rates above the national benchmark, creating demand for silver-alloy, nitrofurazone-coated, and hydrogel Foley catheters. The addressable U.S. antimicrobial urinary catheter segment is estimated at USD 1.3 billion in 2025, with hospital med-surg and long-term care accounts as the primary buyers.
Home-based intermittent catheterization is the second opportunity. Single-use hydrophilic catheters reduce infection risk relative to indwelling devices, and home-care demand grows as Medicare coverage for home catheter supplies expands. The estimated addressable spend in U.S. home intermittent catheters is USD 0.9 billion in 2025, with pharmacy and direct-to-consumer channels still underpenetrated relative to durable medical equipment suppliers.
Market at a Glance
| Metric | Detail |
|---|---|
| Market Size 2024 | USD 6.8 billion |
| Market Size 2032 | USD 9.9 billion |
| Growth Rate (CAGR) | 4.8% |
| Most Critical Decision Factor | Reimbursement alignment and infection-prevention compliance under CMS rules |
| Largest Region | South (U.S. Census Region) |
| Competitive Structure | Consolidated top tier; Becton Dickinson, Medtronic, and Teleflex hold the majority share |
Leading Market Participants
- Becton Dickinson
- Medtronic
- Teleflex
- Boston Scientific
- Cardinal Health
- Cook Medical
- Merit Medical
- Coloplast
- Hollister
- Avanos Medical
Regulatory and Policy Environment
FDA oversight runs through the Federal Food, Drug, and Cosmetic Act and the Medical Device User Fee Amendments, with MDUFA V setting review performance commitments through fiscal year 2027. Urological catheters are classified under 21 CFR Part 876, and cardiovascular catheters under 21 CFR Part 870. Under 21 CFR Part 803, manufacturers must file Medical Device Reports within 30 calendar days of becoming aware of a reportable serious injury or malfunction.
Reimbursement policy sets the commercial rules. CMS's Hospital-Acquired Condition Reduction Program reduces total Medicare payments by one percent for hospitals in the worst-performing quartile on infection measures. The DMEPOS Competitive Bidding Program, authorized under Section 1847 of the Social Security Act, sets competitive single payment amounts for home medical supplies. Hospitals also follow the CDC's 2009 Guideline for Prevention of Catheter-Associated Urinary Tract Infections in device-use protocols.
Long-Term Outlook for U.S. Catheters
By 2032 the U.S. catheters market is projected to reach USD 9.9 billion, growing at a CAGR of 4.8 percent from the 2025 base year. Growth will concentrate in hydrophilic home catheters, dialysis access devices, and antimicrobial urinary products, while standard indwelling Foley volume plateaus. Hospital procurement will tilt toward suppliers that provide bundled infection surveillance data alongside product supply.
Market structure will consolidate further through acquisitions and private-equity activity, with the top three suppliers holding more than half of revenue by 2032. Tariff exposure and domestic manufacturing commitments will determine supplier eligibility in federal and VA contracts. Entrants that pair home-care distribution with reimbursement support will capture the most durable share of growth.
Frequently Asked Questions
Market Segmentation
- Indwelling Urinary Catheters
- Central Venous Catheters
- Intermittent Catheters
- Cardiovascular Catheters
- Dialysis Catheters
- Hospitals
- Ambulatory Surgery Centers
- Dialysis Centers
- Home Healthcare
- Long-Term Care Facilities
- Group Purchasing Organizations
- Direct Hospital Sales
- Durable Medical Equipment Suppliers
- Retail Pharmacies
- Online Channels
Table of Contents
Research Framework and Methodological Approach
Information
Procurement
Information
Analysis
Market Formulation
& Validation
Overview of Our Research Process
MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.
1. Data Acquisition Strategy
Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.
- Company annual reports & SEC filings
- Industry association publications
- Technical journals & white papers
- Government databases (World Bank, OECD)
- Paid commercial databases
- KOL Interviews (CEOs, Marketing Heads)
- Surveys with industry participants
- Distributor & supplier discussions
- End-user feedback loops
- Questionnaires for gap analysis
Analytical Modeling and Insight Development
After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.
2. Market Estimation Techniques
MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.
Bottom-up Approach
Aggregating granular demand data from country level to derive global figures.
Top-down Approach
Breaking down the parent industry market to identify the target serviceable market.
Supply Chain Anchored Forecasting
MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.
Supply-Side Evaluation
Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.
3. Market Engineering & Validation
Market engineering involves the triangulation of data from multiple sources to minimize errors.
Extensive gathering of raw data.
Statistical regression & trend analysis.
Cross-verification with experts.
Publication of market study.
Client-Centric Research Delivery
MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.